Table 2 Pathologic characteristics associated with sentinel lymph node detection
SLN-negative group (n = 17) | SLN-positive group (n = 48) | p | |
|---|---|---|---|
Tumor size (cm) ≤ 1 cm 1.1 − 2 cm 2.1 − 3 cm ≥ 3.1 cm | 1 (5.9) 7 (41.2) 7 (41.2) 2 (11.8) | 12 (25.0) 22 (45.8) 8 (16.7) 6 (12.5) | 0.13 |
Location Central Peripheral | 2 (11.8) 15 (88.2) | 5 (10.4) 43 (89.6) | 0.88 |
Histology Adenocarcinoma Squamous cell carcinoma Others | 8 (47.1) 7 (41.2) 2 (11.8) | 36 (75.0) 8 (16.7) 4 (8.3) | 0.09 |
T stage T1a T1b T1c T2a T2b | 1 (5.9) 5 (29.4) 6 (35.3) 4 (23.5) 1 (5.9) | 12 (25.0) 19 (39.6) 7 (14.6) 10 (29.8) 0 (0) | 0.14 |
N stage N1 N2 | 1 (5.9) 0 (0) | 3 (6.3) 2 (4.2) | 0.44 |
Stage IA IB IIA IIB IIIA | 11 (64.7) 4 (23.5) 1 (5.9) 1 (5.9) 0 (0) | 36 (75.0) 7 (14.6) 1 (2.1) 2 (4.2) 2 (4.2) | 0.74 |
Visceral pleural invasion PL0 + PL1 PL2 | 2 (11.8) 0 (0) | 4 (8.3) 1 (2.1) | 0.88 |
Visceral pleural distance (cm) | 0.55 ± 0.73 | 0.45 ± 0.57 | 0.5 |
STAS | 9 (52.9) | 19 (39.6) | 0.34 |
Perineural neoplastic invasion | 1 (5.9) | 1 (2.1) | 0.44 |
Vascular invasion | 4 (23.5) | 10 (20.8) | 0.82 |
EGFR mutation | 0 (0) | 4 (8.3) | 0.16 |
PD-L1 status PD-L1 < 1% PD-L1 1 − 49% PD-L1 ≥ 50% | 8 (47.1) 5 (29.4) 4 (23.5) | 28 (63.6) 12 (27.3) 4 (9.1) | 0.245 |
KRAS mutation | 5 (29.4) | 8 (16.7) | 0.45 |